This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



AboutTherapeutic IndicationsRheumatoid arthritisJuvenile idiopathic arthritisPsoriatic arthritisAxial spondyloarthritisPlaque psoriasis & Paediatric plaque psoriasisMechanism of actionMechanism of actionDosingDosingRheumatoid arthritis, psoriatic arthritis & axial spondyloarthritisJuvenile idiopathic arthritisPlaque psoriasisPaediatric plaque psoriasisAdministration & storageAdministrationMYCLIC®StorageEfficacy & SafetyEfficacy & SafetyRheumatoid arthritisAxial spondyloarthritisPsoriatic arthritisPlaque psoriasisJuvenile idiopathic arthritisSupport & ResourcesMaterials
Transforming patients’ lives today and tomorrow1

Enbrel® is a TNF inhibitor approved for treating multiple chronic diseases in rheumatology and dermatology2

  • Over 30 years of partnership and experience3
  • Etanercept has over 7 million patient-years' exposure across indications – and counting4
  • Approved by the EMA in 20005 , Enbrel was the first approved TNFi in RA1

Etanercept is manufactured in Pfizer's state-of the-art manufacturing facility in Grange Castle, Dublin.6

Mechanism of action

Enbrel® is a soluble tumour necrosis factor (TNF) receptor fusion protein2

Learn more about the mechanism of action

Enbrel is approved across 7 therapeutic indications, including paediatric indications²

Review Enbrel indications
Efficacy & Safety

Learn more about the efficacy and safety of Enbrel across licensed indications

Learn more
Enbrel Dosing & Administration

Learn about the recommended dosing for Enbrel and the devices available to your patients to help their at-home management

Learn more
Support & Resources

See what resources are available to support you and your patients

Access resources
AS: Ankylosing spondylitis; axSpA: Axial spondyloarthritis; JIA: Juvenile idiopathic arthritis; Nr-axSpA: Non-radiographic axial spondyloarthritis; Paed: Paediatric; PsA: Psoriatic arthritis; Pso: Psoriasis; RA: Rheumatoid arthritis; TNFi: Tumour necrosis factor inhibitor.

Please refer to the ENBREL Summary of Product Characteristics for full prescribing information

References:Scott, LJ. Drugs. 2014;74:1379-410.Enbrel Summary of Product Characteristics.Pfizer data on file. Years of experience. June 1992.Pfizer data on file. Patient years. March 2020. EMA approval for Enbrel. Available from:
Date accessed: May 2023.
Enbrel EPAR Product Information.

Legal Category: S1A
Further information is available upon request

PP-ENB-IRL-0268 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2024 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024